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Coronary artery disease is the leading cause of mortality and morbidity in the chronic
kidney disease (CKD) population and often presents with atypical symptoms. Current diag-
nostic investigations of myocardial ischemia in CKD lack sensitivity and specificity or may
have adverse effects. We present a case vignette and explore the challenges of diagnostic
myocardial stress investigation in patients with CKD.
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CASE VIGNETTE
A 60-year-old woman with stage 5 chronic kidney disease (CKD)
from glomerulonephritis presented with atypical chest discomfort
at rest. She is worried about coronary artery disease (CAD). She
has hypertension treated with an angiotensin converting enzyme
inhibitor and a beta blocker. Her total cholesterol is 5 mmol/L with
low-density lipoprotein of 3.2 mmol/L. She has no diabetes mel-
litus, no family history of premature CAD, and does not smoke.
How should she be evaluated?
CLINICAL PROBLEM
Cardiovascular disease (CVD) is the leading cause of mortality and
a major cause of morbidity in the CKD population. Myocardial
ischemia is a major cause of death in CKD patients. Myocardial
ischemia can be caused by both epicardial and microvascular CAD.
Coronary artery disease is highly prevalent in the CKD popu-
lation (1) being evident even in early renal disease (2, 3) and in
young CKD patients (4). CKD patients have both traditional and
non-traditional cardiac risk factors (Table 1).
In the CKD population, CAD is often multi-vessel and causes
silent or asymptomatic myocardial ischemia (5, 6). Asymptomatic
epicardial CAD has been detected even in people with early stage
CKD (7) and is associated with a higher major adverse cardiac
event rate compared to those without CAD (6). While the coronary
plaque characteristics in patients with CKD showed no differ-
ence in the prevalence of high-risk plaque compared to the group
without CKD (8), Kawai et al. showed that patients with mild
CKD had higher prevalence of severe epicardial CAD compared
to those without CKD (8), thus, suggesting that the problem relates
to coronary stenosis rather than plaque stability.
Microvascular CAD is also present in the CKD population.
Charytan et al. assessed mild to moderate CKD subjects with-
out diabetes or uncontrolled hypertension using positron emis-
sion tomography imaging and found that the CKD cohort had
decreased coronary flow reserve (CFR) compared to controls (9).
Chade et al. suggested that microvascular dysfunction occurred in
early CKD (10). They performed coronary flow wire to the left
anterior descending artery using adenosine on early CKD sub-
jects with no angiographically significant CAD and found the
CKD subjects had lower CFR compared to normal controls (10).
Microvascular CAD has been shown to be associated with reduced
survival, although, similar to patients without CKD, the rate of
survival is better than for epicardial CAD (11).
STRATEGIES AND EVIDENCE
DIAGNOSTIC EVALUATION
Diagnostic evaluation starts with a thorough clinical history and
examination and a baseline 12-lead ECG. Cardiovascular examina-
tion, especially to exclude uncontrolled hypertension or significant
aortic stenosis is important prior to cardiac stress investigation.
Cardiac stress investigations in CKD patients and their limitations
are outlined in Table 2.
EXERCISE STRESS ECG
In patients with normal renal function, exercise stress test (EST)
with ECG has a low to moderate sensitivity and specificity,
68± 16% and 77± 17%, respectively, even when adequate exer-
cise capacity and 85% heart rate is achieved (12). EST is further
limited in the advanced CKD population, with poor sensitivity of
36% (13) (especially those undergoing dialysis), as decondition-
ing leads to reduced exercise capacity (14). Deconditioning can
be due to vascular, neurological or musculoskeletal comorbidities,
and the catabolic/cachexic metabolic state associated with CKD.
CKD patients have also been shown to have impaired heart rate
response to exercise (15), and the frequently abnormal baseline
ECG in CKD patients (often secondary to hypertension) hampers
the interpretation of standard stress testing. In advanced CKD
patients, the ST segment changes at stress were shown to be not
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significantly different between non-severe CAD and severe CAD
group, despite a longer treadmill exercise time in the non-severe
group (13).
EXERCISE STRESS ECHOCARDIOGRAPHY AND DOBUTAMINE STRESS
ECHOCARDIOGRAPHY
Exercise stress echocardiography (ESE) is better than the standard
stress ECG in ruling in CAD (Positive likelihood ratio ESE 7.94 ver-
sus EST 3.57) and ruling out CAD (Negative likelihood ratio ESE
0.19 versus EST 0.38) (16). Its sensitivity has been reported rang-
ing from 71 to 97% with specificity ranging from 64 to 90% (17).
However, the utility of ESE in CKD population remains limited
due to the same physical reasons as EST limitations above.
The addition of echocardiography allows assessment of ven-
tricular size and function, aortic and mitral valvular calcification,
left ventricular hypertrophy (LVH), and potentially CFR. CFR
measurement by Doppler echocardiography in the left anterior






Hypertension Left ventricular hypertrophy
Diabetes mellitus Fluid overload
Dyslipidemia Uremia
Smoking Anemia
Family history of coronary artery
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descending artery has been shown to be a determinant of cardiac
events in CKD patients in the absence of obstructive epicardial
CAD (18), although this is not performed routinely by many
echocardiography laboratories due to technical difficulties.
Dobutamine and dipyridamole stress echocardiography (DSE)
technique detects inducible myocardial ischemia based on detec-
tion of wall motion abnormalities, thus, would detect significant
epicardial CAD, not microvascular disease.
A meta analysis in 2008 showed that dipyridamole and dobu-
tamine stress echocardiography had a sensitivity of 85% (con-
fidence interval 80–89) and 86% (confidence interval 78–91),
respectively, and a specificity of 89% (confidence interval 82–94)
and 86% (confidence interval 75–89), respectively, in detecting
myocardial ischemia in the non-renal population (19). It is often
recommended as a screening test in advanced CKD patients.
A systematic review in 2011 identified 11 DSE studies with 690
potential renal transplant recipients (19). Overall, DSE had mod-
erate sensitivity of 80% (confidence interval 64–90) in detecting
inducible myocardial ischemia in renal transplant candidates (20).
Several mechanisms may explain the reduced accuracy of DSE in
the advanced CKD population. The majority of advanced CKD
patients had a blunted chronotropic response, thus, did not achieve
85% maximal predicted heart rate despite the use of atropine, sig-
nificantly reducing the sensitivity of DSE in detecting myocardial
ischemia (21). The thick myocardium due to LVH with small intra-
cavitary volume, commonly found in CKD patients, obscures the
detection of wall motion abnormalities at stress, thus, significantly
reducing the sensitivity of stress echocardiography in detecting
inducible myocardial ischemia in CKD population. Microvascu-
lar CAD is difficult to appreciate given the focus on regional wall
motion abnormality and likely to be missed.
Abnormal DSE results in CKD patients have been associated
with poorer prognosis for cardiac events and overall mortality (13,
22–24). Bergeron et al. showed that among 485 patients with CKD,
Table 2 | Cardiac stress investigations in the normal renal function versus advanced chronic kidney disease (CKD) patients.
Cardiac stress modalities Sensitivity (%) Specificity (%) Issues
Normal renal CKD Normal renal CKD
function function
Exercise stress ECG 68 (52–84) 36 (21–54) 77 (60–94) 91 (83–96) Reduced exercise capacity (deconditioning)
Impaired chronotropic response







Reduced exercise capacity (deconditioning)
Impaired chronotropic response
Abnormal baseline ECG and left ventricular hypertrophy
Pharmacological stress
echocardiography
86 (78–91) 80 (64–90) 86 (75–89) 89 (79–94) Blunted chronotropic response
Left ventricular hypertrophy
Microvascular disease potentially can be missed
Myocardial perfusion
scintigraphy
89 69 (48–85) 75 77 (59–89) False negative results in multi-vessel disease due to
balanced ischemia
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the percentage of ischemic segments during DSE was an indepen-
dent predictor of mortality (22). Negative stress echocardiography
results, on the other hand, have been shown to be associated with
low incidence of major adverse cardiac events (21).
Blunted chronotropic response with exercise in CKD popula-
tion may relate to poorer overall cardiac prognosis. A 2012 meta
analysis of 11,542 patients showed that submaximal age-predicted
heart rate (<85% maximum heart rate) in the setting of nor-
mal ESE and DSE had higher cardiovascular risk than those who
achieved >85% maximal predicted heart rate (25).
MYOCARDIAL PERFUSION SCINTIGRAPHY
Exercise and pharmacological myocardial perfusion scintigraphy
(MPS) have sensitivity of 87 and 89%, and specificity of 73 and
75%, respectively, in detecting >50% coronary artery stenosis
in patients without advanced CKD (26). Exercise MPS in the
advanced CKD population has the same limitation as EST and
ESE, i.e., related to the inadequate exercise performance and
chronotropic incompetence (27).
A systematic review in 2011 showed that MPS has sensitiv-
ity of 69% (confidence interval 48–85) and specificity of 77%
(confidence interval 59–89) in diagnosing inducible myocardial
ischemia in the pre-renal transplant population (20). MPS has
high false negative result in detecting ischemia in people with sig-
nificant triple vessel CAD, as in the CKD population, because of
homogeneous tracer uptake due to “balanced ischemia” (28, 29).
Normal myocardial perfusion measured by SPECT may not be
associated with excellent prognosis in CKD population unlike the
normal population (30, 31), perhaps due to the high-false negative
result from balanced ischemia. Hakeem et al. showed patients with
CKD with normal MPS still had a three times higher cardiac death
rate than those with normal MPS and no CKD (31). In addition,
concurrent reduced CFR and LVH may play a role. Fukushima et al.
reported CKD patients with normal clinical myocardial perfusion
by PET scan had reduced global myocardial flow reserve, which
implied an underlying microvascular dysfunction in this popula-
tion (32) that could explain the poorer prognosis. Increased base-
line myocardial blood flow and peripheral endothelial dysfunction
in CKD patients have been suggested by Koivuviita et al. (33).
Nonetheless, abnormal MPS results in CKD patients have been
shown to be associated with a higher incidence of cardiac events
and mortality (34–40). A meta analysis of 12 studies of pre-
renal transplant patients showed that the presence of reversible
defects of inducible myocardial ischemia was associated with six-
fold increased risk of myocardial infarction and almost fourfold
risk of cardiac death (41). The presence of fixed defects was asso-
ciated with a nearly fivefold increased risk of cardiac death (41).
Joki et al. suggested that myocardial perfusion abnormalities sig-
nificantly predicted cardiac events in CKD patients independently
of eGFR and left ventricular ejection fraction (34). Among 2967
patients with CKD, the incidence of major adverse cardiac events
at 1 year was 1.0, 3.9, 5.9, and 7.3% for normal, mild, moder-
ate, and severe summed stress score, respectively (36). Al-Mallah
et al. demonstrated that an interaction between renal function
and the magnitude of perfusion deficit assessed by stress MPS
in patients with moderate and severe CKD in the presence of
abnormal MPS (38).
Blunted heart rate response in CKD patients during stress
myocardial perfusion imaging has been reported to be associated
with increased mortality (42–44).
CARDIOVASCULAR MAGNETIC RESONANCE
Cardiovascular magnetic resonance (CMR) with gadolinium con-
trast has not been widely utilized clinically in the CKD population
due to the concern of nephrogenic systemic fibrosis (NSF) (45–
47). The use of Gadolinium chelates is prohibitive in CKD patients
due to the rare but serious side effect of NSF. NSF manifests as a
hardening of the skin and internal organs resembling scleroderma,
which is irreversible and potentially fatal.
Cardiovascular magnetic resonance spectroscopy has been
studied to assess early cardiac dysfunction in pediatric population
with advanced CKD (48). Dobutamine stress CMR was shown to
be safe in the pre-renal transplant population (49).
RECOMMENDATION
Exercise tolerance has utmost importance both for prognosis
and symptoms capacity and has implication in the case of peri-
operative risk assessment (50), in this case, renal transplantation.
Therefore, we recommend ESE to the case vignette described,
to exclude inducible myocardial ischemia, inducible arrhythmia,
and to assess exercise capacity and symptoms objectively. Resting
echocardiography is useful to exclude significant aortic stenosis
prior to exercise stress and to visually assess the degree of LVH.
FUTURE DEVELOPMENTS
Further research is needed for better diagnostic testing for myocar-
dial ischemia in CKD. A new non-contrast blood oxygen level
dependent (BOLD) CMR technique has been utilized in several
human studies to assess myocardial oxygenation as a measure of
ischemia with promising benefits (51–57), namely, in syndrome
X, hypertensive patients, patients with CAD, hypertrophic car-
diomyopathy, and aortic stenosis. It detects both epicardial and
microvascular CAD without the use of potentially toxic Gadolin-
ium chelate contrast agents. The combination of non-contrast
BOLD CMR and non-contrast whole-heart magnetic resonance
coronary angiography, which can characterize significant proximal
epicardial CAD, has potential for assessing myocardial ischemia
in the advanced CKD population. This needs to be tested in
prospective studies.
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